8-K: Cognition Therapeutics Reports Positive Phase 2 Alzheimer's Data and Third Quarter 2024 Financial Results

Cognition Therapeutics announced promising results from its Phase 2 SHINE study, showing a significant slowing of cognitive decline in a subgroup of Alzheimer's patients, along with its third quarter 2024 financial results.

Summary

• Cognition Therapeutics reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company highlighted positive results from a pre-specified analysis of its Phase 2 SHINE study of CT1812 in Alzheimer's patients.
• A subgroup of patients with lower levels of plasma p-tau217 showed a 95% slowing of cognitive decline on the ADAS-Cog11 scale and a 108% slowing on the MMSE scale.
• Cognition is planning to request an end-of-Phase 2 meeting with the FDA to discuss the safety and efficacy of CT1812 and to seek alignment on a Phase 3 program design.
• Topline results from the Phase 2 SHIMMER study in dementia with Lewy bodies (DLB) are expected by the end of 2024.
• The company's cash and cash equivalents were approximately $22.0 million as of September 30, 2024, with an additional $53.6 million in grant funds remaining from the NIA.
• Cognition estimates that it has sufficient cash to fund operations into the second quarter of 2025.
• Research and development expenses were $11.4 million for the third quarter of 2024, compared to $11.7 million for the same period in 2023.
• The company reported a net loss of $9.9 million, or $(0.25) per share, for the third quarter of 2024, compared to a net loss of $6.7 million, or $(0.22) per share, for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, which are tempered by the company's financial position and ongoing losses. The strong efficacy data is a significant positive, but the need for further funding and the risks associated with clinical development temper the overall sentiment.

Positives

• The Phase 2 SHINE study showed a significant slowing of cognitive decline in a subgroup of Alzheimer's patients treated with CT1812.
• The company is actively advancing CT1812 in Alzheimer's disease and plans to meet with the FDA to discuss a Phase 3 program.
• Topline results from the Phase 2 SHIMMER study in DLB are expected by the end of 2024.
• The company has sufficient cash to fund operations into the second quarter of 2025.
• The company has $53.6 million in grant funds remaining from the NIA.

Negatives

• The company reported a net loss of $9.9 million for the third quarter of 2024, which is higher than the $6.7 million loss in the same period of 2023.
• The company's cash balance decreased from $29.9 million at the end of 2023 to $22.0 million as of September 30, 2024.

Risks

• The company's future success depends on the successful advancement of its product candidates through clinical trials and regulatory approvals.
• There are uncertainties inherent in the results of preliminary data and earlier-stage clinical trials being predictive of later-stage clinical trials.
• The company faces competition and may be affected by economic, business, or competitive factors.
• The company's ability to secure new and retain existing grant funding is a risk.
• The company's ability to maintain its Nasdaq listing is a risk.

Future Outlook

The company expects to report topline results from the Phase 2 SHIMMER study in DLB by the end of 2024 and plans to request an end-of-Phase 2 meeting with the FDA to discuss the CT1812 program in Alzheimer's disease.

Management Comments

• Lisa Ricciardi, Cognition's president and CEO, stated that the Phase 2 SHINE study results are one of the most important milestones in the company's history.
• Ms. Ricciardi noted that the data presented at CTAD showed a near-total preservation of cognition in a subgroup of Alzheimer's patients treated with CT1812 who had p-tau217 levels below median.
• Ms. Ricciardi also mentioned that the company is moving rapidly to advance CT1812 in Alzheimer's disease and will seek alignment with the FDA on a pivotal Phase 3 program design.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for neurodegenerative diseases, particularly Alzheimer's and dementia with Lewy bodies, where there is a high unmet medical need. The positive results for CT1812 in a subgroup of Alzheimer's patients could represent a significant step forward in the development of disease-modifying therapies.

Comparison to Industry Standards

• The 95% and 108% slowing of cognitive decline in the SHINE study subgroup is a very strong result compared to other Alzheimer's trials, where even modest improvements are often considered clinically meaningful.
• For example, recent trials of anti-amyloid antibodies have shown a slowing of cognitive decline of around 25-35% on similar scales, making the results of CT1812 in this subgroup particularly noteworthy.
• The focus on p-tau217 levels as a biomarker to identify patients who may respond better to treatment is also in line with current trends in Alzheimer's research, which is moving towards more personalized approaches.
• The company's focus on DLB is also important, as this is an understudied area with few available treatments, and the SHIMMER study results are eagerly awaited.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results, but negatively to the financial losses.
• Employees may be encouraged by the progress of the clinical programs.
• Patients with Alzheimer's and DLB may have increased hope for new treatment options.
• Creditors may be concerned about the company's cash burn rate.

Next Steps

• The company plans to request an end-of-Phase 2 meeting with the FDA to discuss the CT1812 program in Alzheimer's disease.
• The company expects to report topline results from the Phase 2 SHIMMER study in DLB by the end of 2024.
• The company will continue enrollment in the Phase 2 START study in early Alzheimer's disease and the Phase 2 MAGNIFY study in geographic atrophy.

Key Dates

Keywords

Alzheimer's disease, dementia with Lewy bodies, CT1812, clinical trials, neurodegenerative disorders, p-tau217, cognitive decline, biopharmaceutical, Phase 2 study, FDA, financial results